Skip to main content


Fig. 2 | BMC Medicine

Fig. 2

From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

Fig. 2

Vaccination strategy: comparison of relative prevalence reduction using fixed treatment numbers of 20/1,000 PWID per year and vaccinating all who were treated and had a SVR (A); vaccinating an equivalent number independently of treatment history in the community (B); and vaccinating everyone not infected (C). Settings with 75, 50 and 25 % initial chronic HCV prevalence among PWID, vaccines with 30, 60 and 90 % efficacies. HCV hepatitis C virus, PWID people who inject drugs

Back to article page